About this Research Topic
Cerebral small vessel disease (CSVD) refers to pathological processes affecting small arteries and veins in the brain leading to both ischemic and hemorrhagic damage. Depending on the context, the term CSVD can also refer to clinical manifestations or neuroimaging markers of vascular damage. When CSVD progresses, it can cause strokes, cognitive impairment, transient ischemic attacks, and transient focal neurological episodes.
The two main forms of CSVD are hypertensive arteriopathy (or arteriolosclerosis) and cerebral amyloid angiopathy. Hypertensive arteriopathy can be found mostly in the deep lenticulostriate arteries, whereas cerebral amyloid angiopathy has a predilection for cortical and leptomeningeal arterioles and arteries. Although hypertensive arteriopathy and cerebral amyloid angiopathy are classically described as separate entities, patients with neuroimaging abnormalities suggestive of a mixed pathology are often encountered.
Detection of early and later stage CSVD, as well as the clinical implications of these markers, is a strongly developing field of research. Although visualization of the vessels themselves is still challenging, radiologic markers associated with CSVD related damage are being increasingly recognized in clinical practice. Besides, new and improved imaging techniques and biomarkers in the cerebrospinal fluid and blood are being discovered. New and improved methods for detection might help characterize and diagnose CSVD in an earlier disease stage.
In this Research Topic, we aim to expand and improve methods of CSVD detection. Papers studying better characterization of mixed-type pathology are also of interest. The types of articles can include but are not limited to Original Research, Reviews, Mini-Reviews, Methods, and Brief Research Reports on CSVD detection.
Manuscripts with the following themes related to pre-clinical and clinical detection of CSVD are especially welcome:
- Biomarkers in blood and cerebrospinal fluid
- Imaging markers on 7 Tesla MRI
- Cerebral amyloid angiopathy detection with positron emission tomography (PET)
- Mixed type CSVD
- Biomarkers and clinical symptoms related to CSVD
The two main forms of CSVD are hypertensive arteriopathy (or arteriolosclerosis) and cerebral amyloid angiopathy. Hypertensive arteriopathy can be found mostly in the deep lenticulostriate arteries, whereas cerebral amyloid angiopathy has a predilection for cortical and leptomeningeal arterioles and arteries. Although hypertensive arteriopathy and cerebral amyloid angiopathy are classically described as separate entities, patients with neuroimaging abnormalities suggestive of a mixed pathology are often encountered.
Detection of early and later stage CSVD, as well as the clinical implications of these markers, is a strongly developing field of research. Although visualization of the vessels themselves is still challenging, radiologic markers associated with CSVD related damage are being increasingly recognized in clinical practice. Besides, new and improved imaging techniques and biomarkers in the cerebrospinal fluid and blood are being discovered. New and improved methods for detection might help characterize and diagnose CSVD in an earlier disease stage.
In this Research Topic, we aim to expand and improve methods of CSVD detection. Papers studying better characterization of mixed-type pathology are also of interest. The types of articles can include but are not limited to Original Research, Reviews, Mini-Reviews, Methods, and Brief Research Reports on CSVD detection.
Manuscripts with the following themes related to pre-clinical and clinical detection of CSVD are especially welcome:
- Biomarkers in blood and cerebrospinal fluid
- Imaging markers on 7 Tesla MRI
- Cerebral amyloid angiopathy detection with positron emission tomography (PET)
- Mixed type CSVD
- Biomarkers and clinical symptoms related to CSVD
Keywords: Cerebral Small Vessel Disease, MRI, Microbleeds, White Matter Hyperintensity, Biomarker
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
